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Pathogen-targeted transcriptional proﬁling in human sputum may elucidate the physiologic state of
Mycobacterium tuberculosis (M. tuberculosis) during infection and treatment. However, whether M.
tuberculosis transcription in sputum recapitulates transcription in the lung is uncertain. We therefore
comparedM. tuberculosis transcription in human sputum and bronchoalveolar lavage (BAL) samples from
11 HIV-negative South African patients with pulmonary tuberculosis. We additionally compared these
clinical samples with in vitro log phase aerobic growth and hypoxic non-replicating persistence (NRP-2).
Of 2179 M. tuberculosis transcripts assayed in sputum and BAL via multiplex RT-PCR, 194 (8.9%) had a p-
value <0.05, but none were signiﬁcant after correction for multiple testing. Categorical enrichment
analysis indicated that expression of the hypoxia-responsive DosR regulon was higher in BAL than in
sputum.M. tuberculosis transcription in BAL and sputumwas distinct from both aerobic growth and NRP-
2, with a range of 396e1020 transcripts signiﬁcantly differentially expressed after multiple testing
correction. Collectively, our results indicate that M. tuberculosis transcription in sputum approximatesM.
tuberculosis transcription in the lung. Minor differences between M. tuberculosis transcription in BAL and
sputum suggested lower oxygen concentrations or higher nitric oxide concentrations in BAL. M. tuber-
culosis-targeted transcriptional proﬁling of sputa may be a powerful tool for understanding M. tuber-
culosis pathogenesis and monitoring treatment responses in vivo.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Understanding the physiologic state and adaptations of Myco-
bacterium tuberculosis (M. tuberculosis) in human patients withty Conference, San Francisco,
Program, University of Colo-
03, 12801 East 17th Avenue,
.J. Garcia).
access article under the CC BY-NCtuberculosis (TB) is important because the effectiveness of antibiotics
depends on the physiologic state of the bacterium [1e3]. It is
therefore essential to develop robust methods for in vivomonitoring
and evaluation of pathogen physiology, since the physiologic state of
M. tuberculosis in human tissues likely differs from the state of M.
tuberculosis in in vitro and murine models of tuberculosis [4e7].
The physiologic state of M. tuberculosis can be deduced in hu-
man clinical samples using pathogen-targeted transcriptional
proﬁling [5,6]. A promising practical application of this technique is
monitoring how drug treatment alters the M. tuberculosis-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tolerant “persister” phenotypes that require prolonged treatment
[5,8,9]. MonitoringM. tuberculosis transcriptional responses during
treatmentmay provide novel pharmacodynamicmeasures that will
enhance evaluation of new drug regimens and help identify pa-
tients who are responding poorly to treatment.
In order to use M. tuberculosis gene expression proﬁling as a
treatment monitoring tool, it is important to determine whetherM.
tuberculosis gene expression in sputum recapitulates bacterial ad-
aptations in the lung. M. tuberculosis rapidly adapts its physiologic
state to environmental conditions [4,10] and therefore could have a
different transcriptional pattern in sputum than in the lung.
Bronchoalevolar lavage (BAL) is an invasive technique for obtaining
alveolar and small airways specimens that more directly samples
the sites of disease within the lung than does sputum [11]. Since
serial collection of BAL for treatment monitoring is infeasible on a
large scale, we sought to determine how similar M. tuberculosis in
sputum is to M. tuberculosis in BAL.
We therefore compared the gene expression patterns of M.
tuberculosis in contemporaneously-collected sputa and BAL ﬂuid.
We also examined and compared these results with in vitro samples
representing two extremes along the continuum of oxygen avail-
ability: the aerobic log-phase growth model and the gradual oxy-
gen deprivation model, known as Non-Replicating Persistence 2
(NRP-2) [12], to examine whether either model reﬂected the in vivo
state. Since transcriptional proﬁling has potential practical appli-
cation for treatment monitoring, we contextualized transcriptional
differences between sputum and BAL by comparison with tran-
scriptional changes induced in human sputum by drug treatment.
Finally, to determine if differences in M. tuberculosis expression
between sputum and BAL might reﬂect different host immune re-
sponses, we assayed selected human genes associated with gran-
uloma formation and inﬂammatory response in the same sputa and
BAL.
2. Methods
2.1. Enrollment and collection of human specimens
HIV-uninfected adults with sputum acid-fast bacillus positive
pulmonary TB were enrolled prior to antibiotic treatment at Stel-
lenbosch University, South Africa. Spontaneously expectorated
sputum was collected 15e30 min post bronchoscopy in approxi-
mately 10 mL of guanidine thiocyanate (GTC) solution (5 M guani-
dinium thiocyanate, 0.5% w/v sodium N-lauryl sarcosine, 25 mM
trisodium citrate, 0.1 M 2-mercaptoethanol, 0.5% w/v Tween 80 [pH
7.0]) per 5 mL sputum, according to published methods [5]. During
bronchoscopy, the right middle lobe bronchus was lavaged with two
60mL aliquots of saline. 15 mL of returned aspirate was immediately
aliquoted into 30 mL GTC solution. Samples were needle-sheared,
centrifuged at 9000  g for 3 min, and stored in Trizol at 80 C.
The Human Research Ethical Committee of the Faculty of Medicine
and Health Sciences at Stellenbosch University approved the study.
All patients provided written informed consent.
2.2. In vitro experiments
M. tuberculosis H37Rv for log phase aerobic growth was grown
in 100 mL 7H9 at 37 C with four replicates. At mid-log phase
growth, 1 mL was transferred to a 250 mL vented ﬂask containing
30 mL 7H9 media (0.05% Tween 80, 0.2% glycerol, 10% ADC sup-
plement) and incubated at 37 C. At mid-log phase growth 20 mL
were transferred into 20 mL of 4M GTC with 10uL B-mercaptoe-
thanol per mL GTC, centrifuged, resuspended in trizol, cells lysed,
and RNA extracted using chloroform.M. tuberculosis for the NRP-2 model was grown in 100mL Dubos
Tween albumin (DTA) at 37 C with 6 replicates. At mid-log phase
growth, 1 mL was transferred into 250 mL of DTA in a 250 mL
vented cap ﬂask, incubated, and grown until an OD600 of 0.40.
Twenty mL were then transferred into a falcon tube, and centri-
fuged at 800 rpm for 3 min to sediment clumped colonies. Then,
170 uL of this culture were transferred into 17 mL of DTA in a test
tube along with a magnetic stir bar. Test tubes were sealed with
paraﬁlm and placed on aWheaton BioStir4 plate with stirring set at
120 rpm. After 14 days, the solution was transferred into 17 mL of
4MGTCwith 10uL B-mercaptoethanol permL GTC, centrifuged, and
resuspended in Trizol. The cells were then lysed and RNA extracted.
2.3. RNA extraction and transcriptional proﬁling
Total RNA was extracted using a phenol/chloroform protocol
described in the Supplementary Materials. We assayed expression
of 2179 selected M. tuberculosis genes (54% of the genome) via
multiplex quantitative RT-PCR (TaqMan) with a LightCycler 480
(Roche, Indianapolis, Indiana) using methods previously described
in detail [5]. A panel of 262 human genes was also assayed due to
their association with inﬂammatory cytokines and immune
response. Details of TaqMan primers are available at http://genes.
stanford.edu/oli/genes.php?organism¼h.
2.4. Data pre-processing
Data from both the in vitro experiments and clinical samples
were batch corrected using a median approach. This median
approach involves taking the median value of genes resampled
across batches and normalizing the subsequent batches to the ﬁrst
batch. Since BAL and sputa were paired samples, theM. tuberculosis
transcriptional data from clinical samples was normalized using a
previously-described minimum variance method [13]. A separate
normalization was then performed on the combined in vitro and
clinical data. As this data was not paired, a median was ﬁrst taken
for each gene, and then the same minimum variance method was
used to normalize each sample to this median.
2.5. Analysis
Differential expression was tested via paired t-tests (between
BAL and sputum from the same patients) and unpaired, unequal
variance t-tests (between clinical samples and in vitro samples)
with Benjamini-Hochberg (BH) multiple testing correction
(Supplemental Data 1). Categorical enrichment in TB-speciﬁc
functional categories [5] (Supplemental Data 2) and Gene
Ontology (GO) [14,15] were evaluated with a modiﬁed Fisher's
exact test [14,16]. We used different gene lists to calculate enrich-
ment for clinical and in vitro data. Since no genes were differentially
expressed between BAL and sputum after correction for multiple
comparisons, we assessed trends in categorical enrichment using
genes with a nominal p-value of <0.05. The resulting categorical
enrichment p-values were then corrected using BHmultiple testing
correction. For comparisons using in vitro data, categorical enrich-
ment was quantiﬁed using genes with a BH-corrected p-value of
<0.05. These categorical enrichments were not further corrected
for multiple comparisons. Because of the potential use of M.
tuberculosis transcriptional proﬁles for treatment monitoring, we
additionally compared differences between sputum and BAL with
transcriptional changes induced by drug treatment. For this anal-
ysis we used our previously-published data on M. tuberculosis
expression in the sputum of patients treated for TB [5], a project
that used the same platform and approximately the same number
of samples.
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the variance of medians of the housekeeping genes: EEF1A1, GAPD,
PPIA, RPL13A. They were then normalized for differential expres-
sion by minimizing the variance of the housekeeping genes of the
paired sputum and BAL samples.
3. Results
3.1. Greater M. tuberculosis mRNA abundance in sputum than in
BAL
mRNA abundance (quantiﬁed as median CT of the 100 most
highly expressed M. tuberculosis transcripts assayed) was lower in
BAL than in sputum (Table S1). Even after adjusting for the dilution
caused by saline used for alveolar lavage (See supplement), M.
tuberculosismRNAwas 8.4-fold more concentrated in sputum than
in BAL. Measurement of M. tuberculosis mRNA was highly repeat-
able (Figure S1).
3.2. Increased expression of DosR in BAL relative to sputum
A paired comparison of sputum with BAL identiﬁed 194 genes
(8.9% of genes assayed) with p-value <0.05, suggesting marginally
higher differences between sputum and BAL than expected by
chance alone. However, after adjustment for multiple comparisons,
no genes were signiﬁcantly differentially expressed.
Although no genes passed multiple comparison adjustment, we
explored trends in gene categories using a nominal p-value
threshold of 0.05 on the genes with multiple testing correction
performed on the categorical enrichments p-values. Enrichment
analysis of functional gene categories in genes with p-value <0.05
showed that expression of genes in the DosR regulon was higher in
BAL than in sputum (adjusted p-value ¼ 0.0012) (Figure 1a). Of the
48 DosR regulon genes, 45 had higher mean expression in BAL.
Bronchoalveolar lavage also had lower expression of ribosome
proteins (adjusted p-value of 0.036).
3.3. Transcription in clinical samples differs markedly from in vitro
models
As expected, the transcriptional proﬁle of NRP-2 was mark-
edly different from transcription in log-phase aerobic growthFigure 1. Expression of key M. tuberculosis and host genes in BAL relative to sputum (
expression of 48M. tuberculosis DosR regulon genes in BAL relative to sputum demonstrates u
relative to sputum is consistent with decreased inﬂammation in BAL.(Figure 2a). Consistent with previous studies [17], hypoxic stress
in NRP-2 was associated with profound up-regulation of the
DosR regulon, oxidative stress responses, and anaerobic
respiration and down-regulation of genes related to growth
and metabolism.
Both in vitromodels were also distinct from the clinical samples.
A Principal Components Analysis plot (Figure 3) shows clusters of
aerobic and NRP-2 samples that are distinct from one another and
also distinct from the clinical samples. By contrast, sputum and BAL
samples partially overlap. This pattern is corroborated by differ-
ential expression testing using an unpaired t-test. A range of
396e1020 genes (18%e47% of genes assayed) was differentially
expressed between clinical and in vitro samples after multiple
comparison correction (Table 1a and Table 1b). Transcription in
sputum and BAL was highly correlated (Pearson ¼ 0.91, Table S2),
while correlation of these clinical samples to in vitro samples was
lower (ranging from 0.74 between BAL and NRP-2 to 0.86 between
sputum and aerobic growth).
Categorical evaluation of transcriptional differences using genes
signiﬁcantly different between clinical and in vitro specimens (p-
value <0.05 after Benjamini-Hochberg multiple comparison testing)
revealed that BAL and sputum had similar enrichment in functional
processes relative to aerobic growth (Figure 2bec). Relative to aer-
obic growth, sputum and BAL had signiﬁcant up-regulation of the
DosR regulon and signiﬁcant down-regulation of ribosomal genes
and primarymetabolism genes (TCA cycle, ATPases, NADH, and acyl/
acetyl CoAs). However, the magnitude of these differences was not
as profound as observed in aerobic respiration compared to NRP-2.
For example, while DosR is upregulated in clinical samples relative
to aerobic growth, clinical samples have signiﬁcantly lower DosR
expression than NRP-2 (Figure 2dee). In addition to lower DosR
expression, sputum and BAL had lower expression of oxidative
stress genes than NRP-2. Finally, Figure 2f indicates that the
magnitude of changes in expression between sputum and BAL is
diminutive relative to comparisons with in vitro data.3.4. Drug effects outweigh differences between sputum and BAL
We compared the relative magnitude of transcriptional differ-
ences between sample type (BAL versus sputum) with transcrip-
tional changes induced by drug treatment. In previously-reported
(5) M. tuberculosis sputum transcriptome data from Ugandans, thelog2 scale). Upregulation shown in blue, downregulation is shown in yellow. A) Mean
p-regulation of DosR in BAL. B) Mean expression of select human immune genes in BAL
Figure 2. Differential expression of categories related to primary metabolic function, oxygen availability, and virulence between clinical and in vitro samples. The proportion
of genes in each category that were signiﬁcantly differentially expressed is illustrated. Genes that did not display statistically signiﬁcant change are not shown. Categories are
ordered from most up-regulated to most down-regulated in NRP2 relative to aerobic growth. Comparison of categorical expression in A) aerobic growth versus NRP-2, B) aerobic
growth versus sputum, C) aerobic growth versus BAL, D) sputum versus NRP-2, E) BAL versus NRP-2, and F) sputum versus BAL.
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and after two days of drug treatment was 785, more than 3-fold
higher than in the BAL-sputum comparisons (454 genes remained
signiﬁcant after multiple comparisons correction). After seven days
of treatment, the number of genes with p-value < 0.05 increased to
1017 (714 remained signiﬁcant after correction for multiple com-
parisons). In contrast to the sputum-BAL comparison, drug treat-
ment did not alter DosR expression, and expression of ESAT genes
decreased signiﬁcantly [5].Figure 3. Principal components plot of the M. tuberculosis transcriptome in
sputum, BAL, the in vitro aerobic-growth model, and the hypoxic non-replicating
persister (NRP-2) model. Transcriptional differences between sputum and BAL are
minor relative to in vitro samples, demonstrating distinctM. tuberculosis phenotypes in
clinical samples.3.5. Decreased expression of key human immune-related genes in
BAL relative to sputum
To determine if the immune milieu of sputum and BAL differ, we
assayed 262 human genes. The number of genes with a nominal p-
value <0.05 was 73 (28%) in sputum versus BAL comparison with
expression of select genes shown in Figure 1b. Relative to sputum,
BAL had decreased expression of inﬂammatory cytokines including
interferon-g, IL-6, IL-8, IL-13, IL-18 and toll-like receptors 1, 2, and 4.4. Discussion
Our analysis identiﬁed only minor differences between M.
tuberculosis transcription in BAL and sputum. BAL had higher
expression of genes of the hypoxia-responsive DosR regulonTable 1
Genes that are signiﬁcantly (a) up- and (b) down-regulated (p < 0.05 after multiple
testing correction) in the column versus the row.
Sputum BAL Aerated NRP2
a. Upregulated genes
Sputum e e e
BAL 0 e e
Aerated 511 277 e
NRP2 520 367 588
b. Downregulated genes
Sputum e e e
BAL 0 e e
Aerated 302 119 e
NRP2 500 208 897
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the differences in M. tuberculosis transcription between BAL and
sputum were minor relative to the massive transcriptional
reprogramming in human sputum samples following drug expo-
sure, suggesting sputum can be a surrogate for BAL in monitoring
treatment response. Comparisonwith in vitro data suggests thatM.
tuberculosis transcriptional patterns in BAL and sputum are distinct
from standard in vitro models and may represent a midpoint on a
spectrum of oxygen availability between aerobic growth and NRP-
2. These ﬁndings suggest that sputum is an acceptable surrogate
sample for monitoring the bacterial physiologic adaptations of M.
tuberculosis in the lower airway of humans with pulmonary
tuberculosis.
Studying pathogen phenotypes in human patients is important
because, as this study reconﬁrmed, the physiologic state of M.
tuberculosis in humans differs from that observed in vitro and in
murine models [4e7]. Systematic evaluation of transcriptional
differences between sputum and invasive sampling like bron-
choscopy is essential because M. tuberculosis rapidly adapts to
environmental perturbations and different sample types could
represent different environments. TB lesions evolve rapidly [18],
displaying a spectrum of cell composition, necrosis and ﬁbrosis, a
range of nutrient availability, pH and oxygen tension and variable
proportions of intra- and extra-cellular bacilli [3,4]. Spontaneously-
expectorated sputum is thought to originate primarily from the air-
liquid interface of necrotic granulomas that drain to airways [3]. We
hypothesize that bronchoscopic lavage may force saline into less-
well-aerated lesions that would not otherwise be open to air-
ways, resulting in relatively greater sampling of hypoxic regions.
Several M. tuberculosis transcriptional proﬁling studies have
been performed using surgical lung specimens [4,7], but lung tissue
has important disadvantages relative to sputum or BAL. Practically
and ethically, lung tissue can be obtained only from patients failing
drug treatment or as management of massive hemoptysis [4,7].
Since drug exposure greatly alters theM. tuberculosis transcriptome
[5], post-treatment lung specimens provide little information about
treatment naïve M. tuberculosis or transcriptional changes that are
induced by drug exposure. On a practical note, longitudinal sputum
sampling is a much more feasible approach, whereas repeating BAL
or surgical lung biopsy would be logistically impractical if not
impossible.
In contrast toM. tuberculosis gene expression, which is relatively
similar in BAL and sputum, host proﬁling revealed differences in
expression of human immune genes between the two sample types.
Speciﬁcally, sputum had a proinﬂammatory transcriptome relative
to BAL.
This report has several limitations. First, this study used BAL
with the intention of obtaining a more direct sample of diseased
regions of the lung than sputum provides. However, in the process
of sampling alveolar spaces and diseased lung segments, BAL also
washes medium to small airways, resulting in a mixed sample that
may include airwayM. tuberculosis destined to appear in sputum. It
is unclear whether any single tissue type could capture the di-
versity and heterogeneity of lesions present in human TB [3]. By
sampling a range of microenvironments, we believe BAL provides
an acceptable aggregate measure of the mean expression pattern of
the M. tuberculosis population in the accessible lower airway of
patients with pulmonary tuberculosis. Second, our in vitro com-
parisons used M. tuberculosis H37Rv, a laboratory strain. Inherent
between-strain differences could confound our comparisons be-
tween clinical and in vitro specimens. Third, comparing BAL-
sputum transcriptional proﬁles during drug treatment would
have been optimal, but repeating bronchoscopy was not feasible.
Since the pre-treatment transcriptional proﬁles were similar be-
tween sputum and BAL, we think it is likely that transcriptionalproﬁles during treatment will be similar between sputum and BAL.
Finally, the relatively small number of participants limited our
statistical power to detect differences between BAL and sputum.
However, it is likely that we identiﬁed differences with meaningful
effect sizes.
4.1. Conclusion
Monitoring M. tuberculosis gene expression proﬁles in clinical
specimens provides a more accurate representation of the physio-
logic state of M. tuberculosis in human disease than samples ob-
tained in experimental models. Our analysis showed that
transcriptional patterns in BAL and sputum were generally similar,
albeit with higher expression of DosR regulon genes in BAL. How-
ever, the differences inM. tuberculosis expression between sputum
and BAL were substantially smaller than changes in expression in
sputum that occur during drug treatment. These results suggest
that transcriptional proﬁling ofM. tuberculosis in sputa can be used
to monitor the physiological state of M. tuberculosis in the lower
airway of patients with pulmonary tuberculosis, and that resulting
information may enable novel insights into drug effects and lead to
the identiﬁcation of pharmacodynamic markers.
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